Advanced in Ewing Sarcoma

Dr. Elizabeth J. Davis

Oncology | Hematology
Vanderbilt Health Clinicians, LLC
3601 The Vanderbilt Clinic, 
Nashville, TN 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
17 Years of Experience
Advanced in Ewing Sarcoma
Vanderbilt Health Clinicians, LLC
3601 The Vanderbilt Clinic, 
Nashville, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elizabeth Davis is an Oncologist and a Hematologist in Nashville, Tennessee. Dr. Davis has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Chondrosarcoma, Angiosarcoma of the Scalp, Angiosarcoma, and Hernia Surgery. Dr. Davis is currently accepting new patients.

Her clinical research consists of co-authoring 51 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2009
Specialties
Oncology
Hematology
Licenses
Internal Medicine in MI
Hospital Affiliations
Vanderbilt University Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

VANDERBILT HEALTH CLINICIANS, LLC
3601 The Vanderbilt Clinic, Nashville, TN 37232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Enrollment Status: Recruiting
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: INBRX-109
Study Phase: Phase 2
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Procedure, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients With Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-Deficient Gastrointestinal Stromal Tumor (GIST)
Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients With Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-Deficient Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Active_not_recruiting
Publish Date: November 24, 2025
Intervention Type: Procedure, Drug
Study Drug: Rogaratinib
Study Phase: Phase 2
Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid Tumors
Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug
Study Drugs: Berzosertib, Irinotecan Hydrochloride
Study Phase: Phase 1
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug, Procedure
Study Drug: Olaparib
Study Phase: Phase 2
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Procedure, Biological, Radiation
Study Drug: Talimogene Laherparepvec
Study Phase: Phase 2
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Other, Drug
Study Drug: Trametinib
Study Phase: Phase 2
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies
Enrollment Status: Completed
Publish Date: November 22, 2024
Intervention Type: Biological
Study Drug: Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody
Study Phase: Phase 1
A Phase I/II Open-Label Trial of CPI-613® (Devimistat) Plus Hydroxychloroquine to Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
A Phase I/II Open-Label Trial of CPI-613® (Devimistat) Plus Hydroxychloroquine to Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
A Phase II Two-Arm Open-Label Study of Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
A Phase II Two-Arm Open-Label Study of Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
Enrollment Status: Terminated
Publish Date: April 20, 2021
Intervention Type: Drug
Study Drugs: Nivolumab, Relatlimab, Ipilimumab
Study Phase: Phase 2
View 13 Less Clinical Trials

51 Total Publications

Desmoid tumor control with liposomal doxorubicin: a dual-center retrospective analysis.
Desmoid tumor control with liposomal doxorubicin: a dual-center retrospective analysis.
Journal: Expert review of anticancer therapy
Published: August 19, 2025
Similar Doctors
Distinguished in Ewing Sarcoma
Dr. Vicki Keedy
Oncology | Hematology Oncology | Hematology
Distinguished in Ewing Sarcoma
Dr. Vicki Keedy
Oncology | Hematology Oncology | Hematology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (0.1 miles away)
615-322-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Vicki Keedy is an Oncologist and a Hematologist Oncology provider in Nashville, Tennessee. Dr. Keedy is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Synovial Sarcoma, Liposarcoma, Hernia Surgery, and Tissue Biopsy.

Experienced in Ewing Sarcoma
Dr. Kristin Ancell
Hematology | Oncology
Experienced in Ewing Sarcoma
Dr. Kristin Ancell
Hematology | Oncology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (0.1 miles away)
615-322-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kristin Ancell is a Hematologist and an Oncologist in Nashville, Tennessee. Dr. Ancell is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Melanoma, Neuroendocrine Tumor, Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, and Gastrostomy.

Experienced in Ewing Sarcoma
Dr. Benjamin Garmezy
Hematology | Oncology
Experienced in Ewing Sarcoma
Dr. Benjamin Garmezy
Hematology | Oncology

Verdi Oncology Tennessee PC

2004 Hayes St, Suite 720, 
Nashville, TN 
 (0.9 miles away)
615-284-2310
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Benjamin Garmezy is a Hematologist and an Oncologist in Nashville, Tennessee. Dr. Garmezy is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Choriocarcinoma, Urothelial Cancer, and Adult Soft Tissue Sarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Davis's expertise for a condition
ConditionClose
View All 20 Distinguished Conditions
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile